NME Half-Year Report: CDER Sets Strong Foundation With 14 Novel Approvals
Executive Summary
More than twice that number of novel agent applications have user fee goals coming up in the second half of 2015, putting FDA in good position to maintain its streak of high annual NME counts.
You may also be interested in...
FDA New Drug Approval Count May Fall Back To Earth In 2016
A repeat of FDA’s record-breaking NME approval performance from recent years looks unlikely, even though the 14 novel approvals in the first half of 2016 equals the first half total for 2015, because almost one-third fewer novel candidates have user fee goals in the second half.
Biologics’ Big Bang: Novel BLAs Balance Breakthroughs And ‘Biobetters’
Both FDA’s biologics and drug centers posted historic BLA approval counts in 2014, combining to clear 21 novel biologics. The class is split between medical breakthroughs and “biobetters” offering incremental improvements, illustrating the maturation of the biotech industry.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.